Evidence map›Paper›PMID 21206954›Full record

ArticleMolecular bioSystems2011

Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies.

Yanhong Li, Hongzhi Cao, Hai Yu, Yi Chen, Kam Lau, Jingyao Qu, Vireak Thon, Go Sugiarto, Xi Chen

Open access · greenAbstract read
In one paragraph

Article in Molecular bioSystems, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 62 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Sialosides Containing 7-ACS infectious diseases · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. SnClBeilstein journal of organic chemistry · 2019
    Article
  12. Synthesis ofFrontiers in immunology · 2019
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yanhong LiDepartment of Chemistry, University of California, One Shields Avenue, Davis, CA 95616, USA. chen@chem.ucdavis.edu.
Hongzhi Cao
Hai Yu
Yi Chen
Kam Lau
Jingyao Qu
Vireak Thon
Go Sugiarto
Xi Chen
University of California System · US

Funding

Studies of Naturally Occurring Structurally Modified CarbohydratesR01GM076360 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CHEN, XI · 2006 to 2010
$1.9M
NIGMS NIH HHS R01 GM076360NIGMS NIH HHS R01GM076360NIGMS NIH HHS R01GM076360-04S1
6 · The paper itself

Abstract

Aberrant expression of human sialidases has been shown to associate with various pathological conditions. Despite the effort in the sialidase inhibitor design, less attention has been paid to designing specific inhibitors against human sialidases and characterizing the substrate specificity of different sialidases regarding diverse terminal sialic acid forms and sialyl linkages. This is mainly due to the lack of sialoside probes and efficient screening methods, as well as limited access to human sialidases. A low cellular expression level of the human sialidase NEU2 hampers its functional and inhibitory studies. Here we report the successful cloning and expression of the human sialidase NEU2 in E. coli. About 11 mg of soluble active NEU2 was routinely obtained from 1 L of E. coli cell culture. Substrate specificity studies of the recombinant human NEU2 using twenty p-nitrophenol (pNP)-tagged α2-3- or α2-6-linked sialyl galactosides containing different terminal sialic acid forms including common N-acetylneuraminic acid (Neu5Ac), non-human N-glycolylneuraminic acid (Neu5Gc), 2-keto-3-deoxy-D-glycero-D-galacto-nonulosonic acid (Kdn), or their C5-derivatives in a microtiter plate-based high-throughput colorimetric assay identified a unique structural feature specifically recognized by the human NEU2 but not two bacterial sialidases. The results obtained from substrate specificity studies were used to guide the design of a sialidase inhibitor that was selective against human NEU2. The selectivity of the inhibitor was revealed by the comparison of sialidase crystal structures and inhibitor docking studies.

Indexed as

Models, MolecularAmino Acid SequenceBacteriaBase SequenceCationsDrug DesignEnzyme ActivationEnzyme InhibitorsEscherichia coliHigh-Throughput Screening AssaysHumansHydrogen-Ion ConcentrationInhibitory Concentration 50KineticsMolecular Sequence DataNeuraminidaseCationsEnzyme InhibitorsNEU2 protein, humanNeuraminidaseRecombinant Proteins

Identifiers

PMID21206954
PMCPMC3114945
OpenAlexW2083173109

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.